S&P 500   3,332.99 (-0.48%)
DOW   27,281.97 (-0.38%)
QQQ   270.62 (-1.46%)
AAPL   443.65 (-2.63%)
MSFT   211.36 (-2.31%)
FB   270.25 (+1.87%)
GOOGL   1,490.56 (-0.96%)
AMZN   3,153.49 (-2.22%)
NVDA   443.52 (-2.18%)
CGC   16.81 (-4.05%)
BABA   248.00 (-6.65%)
TSLA   1,423.58 (-4.43%)
MU   48.30 (-0.82%)
GE   6.39 (+0.79%)
AMD   83.52 (-3.68%)
T   29.88 (+0.13%)
F   6.85 (-1.15%)
ACB   10.08 (-2.23%)
GILD   68.92 (+0.16%)
NFLX   489.25 (-3.90%)
DIS   130.22 (-0.46%)
BAC   26.00 (+2.08%)
BA   169.64 (-1.49%)
S&P 500   3,332.99 (-0.48%)
DOW   27,281.97 (-0.38%)
QQQ   270.62 (-1.46%)
AAPL   443.65 (-2.63%)
MSFT   211.36 (-2.31%)
FB   270.25 (+1.87%)
GOOGL   1,490.56 (-0.96%)
AMZN   3,153.49 (-2.22%)
NVDA   443.52 (-2.18%)
CGC   16.81 (-4.05%)
BABA   248.00 (-6.65%)
TSLA   1,423.58 (-4.43%)
MU   48.30 (-0.82%)
GE   6.39 (+0.79%)
AMD   83.52 (-3.68%)
T   29.88 (+0.13%)
F   6.85 (-1.15%)
ACB   10.08 (-2.23%)
GILD   68.92 (+0.16%)
NFLX   489.25 (-3.90%)
DIS   130.22 (-0.46%)
BAC   26.00 (+2.08%)
BA   169.64 (-1.49%)
S&P 500   3,332.99 (-0.48%)
DOW   27,281.97 (-0.38%)
QQQ   270.62 (-1.46%)
AAPL   443.65 (-2.63%)
MSFT   211.36 (-2.31%)
FB   270.25 (+1.87%)
GOOGL   1,490.56 (-0.96%)
AMZN   3,153.49 (-2.22%)
NVDA   443.52 (-2.18%)
CGC   16.81 (-4.05%)
BABA   248.00 (-6.65%)
TSLA   1,423.58 (-4.43%)
MU   48.30 (-0.82%)
GE   6.39 (+0.79%)
AMD   83.52 (-3.68%)
T   29.88 (+0.13%)
F   6.85 (-1.15%)
ACB   10.08 (-2.23%)
GILD   68.92 (+0.16%)
NFLX   489.25 (-3.90%)
DIS   130.22 (-0.46%)
BAC   26.00 (+2.08%)
BA   169.64 (-1.49%)
S&P 500   3,332.99 (-0.48%)
DOW   27,281.97 (-0.38%)
QQQ   270.62 (-1.46%)
AAPL   443.65 (-2.63%)
MSFT   211.36 (-2.31%)
FB   270.25 (+1.87%)
GOOGL   1,490.56 (-0.96%)
AMZN   3,153.49 (-2.22%)
NVDA   443.52 (-2.18%)
CGC   16.81 (-4.05%)
BABA   248.00 (-6.65%)
TSLA   1,423.58 (-4.43%)
MU   48.30 (-0.82%)
GE   6.39 (+0.79%)
AMD   83.52 (-3.68%)
T   29.88 (+0.13%)
F   6.85 (-1.15%)
ACB   10.08 (-2.23%)
GILD   68.92 (+0.16%)
NFLX   489.25 (-3.90%)
DIS   130.22 (-0.46%)
BAC   26.00 (+2.08%)
BA   169.64 (-1.49%)
Log in

NASDAQ:TRVNTrevena Stock Price, Forecast & News

$2.41
-0.02 (-0.82 %)
(As of 08/7/2020 02:19 PM ET)
Add
Compare
Today's Range
$1.73
Now: $2.41
$2.86
50-Day Range
$1.41
MA: $1.84
$2.94
52-Week Range
$0.46
Now: $2.41
$3.48
Volume719,843 shs
Average Volume7.62 million shs
Market Capitalization$258.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.93
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Read More
Trevena logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRVN
CUSIPN/A
Phone610-354-8840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30,000.00
Book Value$0.32 per share

Profitability

Net Income$-24,870,000.00

Miscellaneous

Employees29
Market Cap$258.30 million
Next Earnings Date8/12/2020 (Estimated)
OptionableOptionable
$2.41
-0.02 (-0.82 %)
(As of 08/7/2020 02:19 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Trevena (NASDAQ:TRVN) Frequently Asked Questions

How has Trevena's stock been impacted by COVID-19 (Coronavirus)?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TRVN shares have increased by 245.8% and is now trading at $2.4150.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Trevena?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Trevena
.

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Trevena
.

How were Trevena's earnings last quarter?

Trevena Inc (NASDAQ:TRVN) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06).
View Trevena's earnings history
.

What price target have analysts set for TRVN?

1 brokerages have issued 1 year price objectives for Trevena's stock. Their forecasts range from $3.50 to $3.50. On average, they anticipate Trevena's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price.
View analysts' price targets for Trevena
.

Has Trevena been receiving favorable news coverage?

News headlines about TRVN stock have been trending positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trevena earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Trevena
.

Who are some of Trevena's key competitors?

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), ADMA Biologics (ADMA), Amplify Energy (AMPY), Amplify Energy (AMPY), Sorrento Therapeutics (SRNE), AEterna Zentaris (AEZS), (CHK), SCYNEXIS (SCYX) and Miragen Therapeutics (MGEN).

Who are Trevena's key executives?

Trevena's management team includes the following people:
  • Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 56)
  • Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. John P. Hamill, VP of Fin. (Age 55)
  • Erin Clark, Sr. Director of Corp. Strategy & Investor Relations
  • Mr. Michael Catalano, VP of Marketing

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include WINTON GROUP Ltd (0.63%), IFP Advisors Inc (0.02%), UBS Group AG (0.02%) and Wedbush Securities Inc. (0.02%). Company insiders that own Trevena stock include John P Hamill, Leon O Moulder Jr and Maxine Gowen.
View institutional ownership trends for Trevena
.

Which major investors are buying Trevena stock?

TRVN stock was acquired by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Wedbush Securities Inc., UBS Group AG, and IFP Advisors Inc. Company insiders that have bought Trevena stock in the last two years include John P Hamill, Leon O Moulder Jr, and Maxine Gowen.
View insider buying and selling activity for Trevena
.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $2.42.

How big of a company is Trevena?

Trevena has a market capitalization of $258.84 million and generates $30,000.00 in revenue each year. The biopharmaceutical company earns $-24,870,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Trevena employs 29 workers across the globe.

What is Trevena's official website?

The official website for Trevena is www.trevena.com.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.